Trazpiroben
- Generic Name
- Trazpiroben
Bioavailability and Food Effect Study of Two Formulations of TAK-906
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Takeda
- Registration Number
- NCT04831502
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04121078
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03849690
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
Phase 2
Completed
- Conditions
- Idiopathic GastroparesisDiabetic Gastroparesis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT03544229
- Locations
- 🇺🇸
Spring Gastroenterology Associates - Houston, Houston, Texas, United States
🇺🇸Biopharma Informatic Houston 2, Houston, Texas, United States
🇺🇸Baptist Diabetes Associates Research, Miami, Florida, United States
A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)
Phase 2
Completed
- Conditions
- Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
- Interventions
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT03268941
- Locations
- 🇺🇸
850 North Kolb Road, Tucson, Arizona, United States
🇺🇸13055 Southwest 42nd Street, Miami, Florida, United States
🇺🇸8200 Southwest 117th Avenue, Miami, Florida, United States
Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants
Phase 1
Completed
- Conditions
- Japanese Healthy Adult Male Participants
- Interventions
- Drug: TAK-906 Placebo
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT03237156
- Locations
- 🇯🇵
Sekino Clinical Pharmacology Clinic, Toshima, Tokyo, Japan
A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03161405
- Locations
- 🇺🇸
Takeda Investigational Site, Lenexa, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath